Gender-dependent reductions in vertebrae length, bone mineral density and content by doxorubicin are not reduced by dexrazoxane in young rats: Effect on growth plate and intervertebral discs

Calcified Tissue International

Volumn 76, Issue 3, 2005, Pages 214-221

  Mwale, F ^a,b   Antoniou, J ^a,b   Heon S ^a   Servant, N ^a   Wang, C ^a   Kirby, G M ^c   Demers, C N ^a   Chalifour, L E ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF GUELPH   (Canada)

Author keywords

Bone density; Dexrazoxane; Doxorubicin; Growth plate; Intervertebral disc

Indexed keywords

DOXORUBICIN; RAZOXANE; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE GROWTH; BONE MINERAL; BONE TURNOVER; CONTROLLED STUDY; FEMALE; FEMUR; GROWTH PLATE; GROWTH RETARDATION; INTERVERTEBRAL DISK; LUMBAR VERTEBRA; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; RAT; SEX DIFFERENCE; TISSUE INJURY; AGE; ANIMAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DENSITOMETRY; DRUG EFFECT; MALE; METABOLISM; RADIOGRAPHY; SEXUAL DEVELOPMENT; SPRAGUE DAWLEY RAT;

AGE FACTORS; ANIMALS; ANTINEOPLASTIC AGENTS; BONE DENSITY; CARDIOVASCULAR AGENTS; DENSITOMETRY; DOXORUBICIN; FEMALE; GROWTH PLATE; INTERVERTEBRAL DISK; MALE; RATS; RATS, SPRAGUE-DAWLEY; RAZOXANE; SEX CHARACTERISTICS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 21344431832     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-004-0304-9     Document Type: Article

References (48)

1. Gertner JM (1999) Childhood and Adolescence. Primer on the Metabolic Bone Diseases and Disorder of Mineral Metabolism, 4th ed, Edited by MJ Flavus, Lippincolt Williams and Wilkins, New York, pp 45-49
2. Baroncelli GI, Saggese G (2000) Critical ages and stages of puberty in the accumulation of spinal and femoral bone mass: the validity of bone mass measurements. Horm Res 54:2-8
3. Root AW (2002) Bone strength and the adolescent. Adolesc Med 13:53-72
4. Ong KK, Ahmed ML, Dunger DB (1999) The role of leptin in human growth and puberty. Acta Paediatr (suppl)88:95-98
5. Leung W, Hudson MM, Strickland DK, et al. (2000) Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol 18:3273-3279
6. Papadakis V, Tan C, Heller G, Sklar C (1996) Growth and final height after treatment for childhood Hodgkin disease. J Pediatr Hematol Oncol 18:272-276
7. Haddy TB, Mosher RB, Reaman GH (2001) Osteoporosis in survivors of acute lymphoblastic leukemia. Oncologist 6:278-285
8. Kaste SC, Jones-Wallace D, Rose SR, et al. (2001) Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia 15:728-734
9. Halton JM, Atkinson SA, Fraher L, et al. (1996) Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res 11:1774-1783
10. van Leeuwen BL, Kamps WA, Hartel RM, et al. (2000) Effect of single chemotherapeutic agents on the growing skeleton of the rat. Ann Oncol 11:1121-1126
11. Shusterman S, Meadows AT (2000) Long-term survivors of childhood leukemia. Curr Opin Hematol 7:217-222
12. Rainsford KD (1989) Doxorubicin is a potent inhibitor of interleukin 1-induced cartilage proteoglycan resorption in vitro. J Pharm Pharmacol 41:60-63
13. Friedlaender GE, Tross RB, Doganis AC, et al. (1984) Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model. J Bone Joint Surg Am 66:602-607
14. Young DM, Fioravanti JL, Olson HM, Prieur DJ (1975) Chemical and morphologic alterations of rabbit bone induced by adriamycin. Calcif Tissue Res 18:47-63
15. Arola OJ, Saraste A, Pulkki K, et al. (2000) Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 60:1789-1792
16. Kumar D, Kirshenbaum LA, Li T, Danelisen I, Singal PK (2001) Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal 3:135-145
17. Green DM, Grigoriev YA, Nan B, et al. (2001) Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group. J Clin Oncol 19:1926-1934
18. Grenier MA, Lipshultz SE (1998) Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 25:72-85
19. Krischer JP, Epstein S, Cuthbertson DD, et al. (1997) Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 15:1544-1552
20. Frost BM, Eksborg S, Bjork O, et al. (2002) Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med Pediatr Oncol 38:329-337
21. Kremer LC, Dalen EC van, Offringa M, et al. (2001) Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 19:191-196
22. Kwok JC, Richardson DR (2000) The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity. Redox Rep 5:317-324
23. Bu'Lock FA, Gabriel HM, Oakhill A, et al. (1993) Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J 70:185-188
24. Schiavetti A, Castello MA, Versacci P, et al. (1997) Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results. Pediatr Hematol Oncol 14:213-222
25. Wexler LH, Andrich MP, Venzon D, et al. (1996) Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14:362-372
26. Schuchter LM, Hensley ML, Meropol NJ, Winer EP for the Americal Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel(2002) 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 20:2895-2903
27. Poole AR, Laverty S, Mwale F (2000) "Endochondral Bone Formation and Development in the Axial and Appendicular Skeleton". In: Henderson JE, Goltzman, D (eds), The Osteoporosis Primer, Cambridge University Press, United Kingdom, pp 3-17
28. Ueda Y (1987) Problems in anti-leukemic drugs chemotherapy of childhood acute leukemia. Nippon Ika Daigaku Zasshi 54:573-580
29. Héon S, Bernier M, Servant N, et al. (2003) Dexrazoxane does not protect against Doxorubicin-induced damage in the young rat. Am J Physiol Heart Circ Physiol 285:499-506
30. Jahnukainen K, Jahnukainen T, Salmi TT, et al. (2001) Amifostine protects against early but not late toxic effects of doxorubicin in infant rats. Cancer Res 61:6423-6427
31. Rivier C (1993) Female rats release more corticosterone than males in response to alcohol: influence of circulating sex steroids and possible consequences for blood alcohol levels. Alcohol Clin Exp Res 17:854-859
32. Samuelsson BO, Marky I, Rosberg S, Albertsson-Wikland K (1997) Growth and growth hormone secretion after treatment for childhood non-Hodgkin's lymphoma. Med Pediatr Oncol 28:27-34
33. Bradney M, Karlsson MK, Duan Y, et al. (2000) Heterogeneity in the growth of the axial and appendicular skeleton in boys: implications for the pathogenesis of bone fragility in men. J Bone Miner Res 15:1871-1878
34. Hefferan TE, Evans GL, Lotinun S, et al. (2003) Effect of gender on bone turnover in adult rats during simulated weightlessness. J Appl Physiol 95:1775-1780
35. Pelker RR, Friedlaender GE, Panjabi MM, et al. (1985) Chemotherapy-induced alterations in the biomechanics of rat bone. J Orthop Res 3:91-95
36. Glackin CA, Murray EJ, Murray SS (1992) Doxorubicin inhibits differentiation and enhances expression of the helix-loop-helix genes Id and mTwi in mouse osteoblastic cells. Biochem Int 28:67-75
37. Kohler G, Shen V, Peck WA (1984) Adriamycin inhibits PTH-mediated but not PGE2-mediated stimulation of cyclic AMP formation in isolated bone cells. Calcif Tissue Int 36:279-284
38. Ibanez L, Potau N, Ong K, Dunger DB, Zegher F De (2000) Increased bone mineral density and serum leptin in non-obese girls with precocious pubarche: relation to low birthweight and hyperinsulinism. Horm Res 54:192-197
39. Qu Q, Perala-Heape M, Kapanen A, et al. (1998) Estrogen enhances differentiation of osteoblasts in mouse bone marrow culture. Bone 22:201-209
40. Samaan NA, deAsis DN Jr., Buzdar AU, Blumenschein GR (1978) Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer 41:2084-2087
41. Turner CH, Roeder RK, Wieczorek A, et al. (2001) Variability in skeletal mass, structure, and biomechanical properties among inbred strains of rats. J Bone Miner Res 16:1532-1539
42. Colvin JS, Bohne BA, Harding GW (1996) Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 12:390-397
43. Wiseman LR, Spencer CM (1998) Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs 56: 385-403
44. Seifert CF, Nesser ME, Thompson DF (1994) Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother 28:1063-1072
45. Mandalunis PM, Cabrini RL, Ubios AM (1997) Iron overloading inhibits endochondral ossification. Acta Odontol Latinoam 10:55-61
46. Johanson NA (1990) Musculoskeletal problems in hemoglobinopathy. Orthop Clin North Am 21:191-198
47. Tchetina E, Mwale F, Poole AR (2003) Distinct phases of coordinated early and late gene expression in growth plate chondrocytes in relationship to cell proliferation, matrix assembly, remodeling, and cell differentiation. J Bone Miner Res 18:844-851
48. Muller I, Niethammer D, Bruchelt G (1998) Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review). Int J Mol Med 1:491-494